Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling
about
Development of Human Membrane Transporters: Drug Disposition and PharmacogeneticsModelling and simulation as research tools in paediatric drug developmentPharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.What is the right dose for children?Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical PracticeTowards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.Development of a population pharmacokinetic model of prucalopride in children with functional constipation.The role of population PK-PD modelling in paediatric clinical research.Clinical trial simulation: a review.Advances in paediatric pharmacokinetics.Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Ontogeny of oral drug absorption processes in children.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Methods for pharmacokinetic analysis in young children.Drug metabolism for the paediatrician.Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success.A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in childrenA novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults.Designing simple PK-PD studies in children.Evidence-based morphine dosing for postoperative neonates and infants.In Silico ADME/Tox Predictions
P2860
Q26786582-58DA9595-C227-4363-BA0A-E359C864FAE8Q27010366-52A2AA85-A7B2-47AE-BDFC-41BC0AF83B32Q30249512-89E590B4-26C0-49D2-AB6C-D3779C8A9795Q34180493-2A78EC90-A1B4-4CD6-8C8C-BCA04DEBFA11Q34393200-9EDB130D-4F7C-4B25-B859-34F5103D0568Q36075844-FA2FB39A-E05D-4194-A60D-209260AA4C05Q36571794-53970ACD-B710-4AC5-AE94-5795F32CECE0Q36729959-0FB82004-B756-452A-8C6C-4655AB8C44CAQ37421978-B88E575F-B80F-419C-A294-D15C54B7A430Q37719346-15689549-556E-4313-B4B6-14E4FE373CFDQ37770955-4D193EB3-2EBE-45E5-A784-ABAB2B958764Q37813680-A28EEF1D-D416-495C-81EB-41DFE8333E70Q37872786-7A265B6B-AE13-47A2-B8C7-9B3E84B076D0Q38017723-61C818C3-3A01-4C97-AD0E-F9CC97B7F120Q38086777-F9493E49-35D6-4BD1-8EA6-25BF0F48C310Q38187157-29DF7718-91FC-4118-9726-5A3A80746204Q38246000-3467CAB9-8B25-43EA-9187-8BE82EEF5191Q38759413-9C92F415-2EE8-4488-B0D6-3C9268EA12B6Q38771392-2FA789BA-FE37-476F-BFE6-B27B39A4DD31Q38857191-282CD746-C75E-4FBD-B4EE-5F67DA132CC1Q39828349-AD166D43-4E0E-486C-B6ED-039BF288EE6EQ41477321-DFB5219F-1A1F-48BC-855E-2DDFA46E09ACQ42569176-6264A2EF-EA22-4353-B136-0D941D0C29AAQ45247905-3B0C5D64-8209-41AF-B1F7-3BAE6ED0E667Q45401802-B30B841C-4582-4B4E-90A9-AFB66006426CQ51115933-CE13399C-2B52-44ED-86B5-A932BCDC1946Q56984194-1BC55691-6982-4FFD-B8E4-DED4C750D869
P2860
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Tailor-made drug treatment for ...... and population PK-PD modeling
@ast
Tailor-made drug treatment for ...... and population PK-PD modeling
@en
Tailor-made drug treatment for ...... and population PK-PD modeling
@nl
type
label
Tailor-made drug treatment for ...... and population PK-PD modeling
@ast
Tailor-made drug treatment for ...... and population PK-PD modeling
@en
Tailor-made drug treatment for ...... and population PK-PD modeling
@nl
prefLabel
Tailor-made drug treatment for ...... and population PK-PD modeling
@ast
Tailor-made drug treatment for ...... and population PK-PD modeling
@en
Tailor-made drug treatment for ...... and population PK-PD modeling
@nl
P2093
P3181
P1433
P1476
Tailor-made drug treatment for ...... and population PK-PD modeling
@en
P2093
Catherijne A J Knibbe
Ibrahim Ince
Meindert Danhof
P304
P3181
P356
10.1016/J.DRUDIS.2008.11.004
P407
P577
2009-03-01T00:00:00Z